Bovill J G, Sebel P S, Stanley T H
Anesthesiology. 1984 Dec;61(6):731-55.
In this article, an attempt has been made to review the use of receptor stimulating pure agonist opioids in anesthesia, especially in patients with cardiovascular disease. Particular emphasis has been placed on the use of opioids in high doses to produce anesthesia, techniques that recently have become popular in cardiovascular anesthesia. A major benefit of opioid anesthesia is the cardiovascular stability obtained during induction and throughout operation, even in patients with severely impaired cardiac function. There is a considerable body of evidence to support this claim when fentanyl is used. Anesthetic doses of morphine are associated with a higher incidence of cardiovascular disturbances and other problems, and, therefore, more attention to detail is required in order to achieve adequate anesthesia and hemodynamic stability. Although other opioids have been used as sole or principal agents in anesthesia for cardiovascular surgery, none have gained widespread acceptance. Meperidine, for example, which is widely used in lower (nonanesthetic) doses as a supplement to nitrous oxide in cardiac and noncardiac surgery, has proved unsuitable because of severe hemodynamic disturbances when high doses are given. However, initial reports concerning two of the newer agonist opioids, sufentanil and alfentanil, suggest that they may prove to be suitable alternatives and perhaps provide advantages over morphine and fentanyl in patients with or without cardiovascular disease. Although cardiovascular stability usually can be assured in the chronically sick cardiac patient with opioid anesthesia, this is not always so with the healthier patient, particularly those presenting for coronary artery surgery. A frequently occurring problem in these patients is hypertension during or after sternotomy, which can result in myocardial ischemia and infarction. The incidence of severe hypertension (increases in systolic blood pressure greater than 20% of control values) can be reduced drastically by increasing the dose of opioid, e.g., up to 140 micrograms/kg of fentanyl. However, despite such large doses, some patients will continue to need treatment with vasodilators, inhalation anesthetics, or other supplements at certain periods during cardiovascular operations. The use of very large doses of opioids also will prolong postoperative respiratory depression. High doses of opioids can reduce or prevent the hormonal and metabolic responses to the stress of surgery. However, even very large doses of fentanyl or its newer analogues do not prevent marked increases in plasma catecholamine concentrations in response to cardiopulmonary bypass.(ABSTRACT TRUNCATED AT 400 WORDS)
在本文中,作者尝试回顾受体激动型纯阿片类激动剂在麻醉中的应用,尤其是在心血管疾病患者中的应用。特别强调了高剂量阿片类药物用于产生麻醉的情况,这种技术最近在心血管麻醉中变得流行起来。阿片类麻醉的一个主要益处是在诱导期及整个手术过程中都能保持心血管稳定,即使是心功能严重受损的患者。当使用芬太尼时,有大量证据支持这一说法。麻醉剂量的吗啡与心血管紊乱及其他问题的发生率较高相关,因此,为了实现充分麻醉和血流动力学稳定,需要更加注重细节。尽管其他阿片类药物已被用作心血管手术麻醉的唯一或主要药物,但没有一种获得广泛认可。例如,哌替啶在心脏和非心脏手术中广泛用于较低(非麻醉)剂量,作为氧化亚氮的补充剂,但当给予高剂量时,由于严重的血流动力学紊乱,已证明不适用。然而,关于两种较新的激动型阿片类药物舒芬太尼和阿芬太尼的初步报告表明,它们可能被证明是合适的替代品,并且在有或没有心血管疾病的患者中可能比吗啡和芬太尼更具优势。虽然在患有慢性疾病的心脏患者中,阿片类麻醉通常可以确保心血管稳定,但在较健康的患者中并非总是如此,尤其是那些接受冠状动脉手术的患者。这些患者中经常出现的一个问题是胸骨切开术期间或之后的高血压,这可能导致心肌缺血和梗死。通过增加阿片类药物的剂量,例如高达140微克/千克的芬太尼,可以大幅降低严重高血压(收缩压升高超过对照值的20%)的发生率。然而,尽管使用了如此大的剂量,一些患者在心血管手术的某些阶段仍需要使用血管扩张剂、吸入麻醉剂或其他补充剂进行治疗。使用非常大剂量的阿片类药物也会延长术后呼吸抑制。高剂量的阿片类药物可以减少或预防对手术应激的激素和代谢反应。然而,即使是非常大剂量的芬太尼或其较新的类似物也不能防止因体外循环而导致的血浆儿茶酚胺浓度显著升高。(摘要截取自400字)